{{medical}}
{{Infobox drug
| IUPAC_name = 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-'''N'''-sulfamoylpropanimidamide
| image = Famotidine.svg
| width = 275
| image2 = Famotidine ball-and-stick model.png

<!--Clinical data-->
| pronounce = {{IPAc-en|f|ə|ˈ|m|ɒ|t|ɪ|d|iː|n}}
| tradename = Pepcid
| Drugs.com = {{drugs.com|monograph|famotidine}}
| MedlinePlus = a687011
| licence_US = Famotidine
| pregnancy_AU = B1
| pregnancy_US = B
| legal_AU = S3
| legal_AU_comment = 或S4
| legal_UK = GSL
| legal_US = OTC
| routes_of_administration = 口服、靜脈注射

<!--Pharmacokinetic data-->
| bioavailability = 40–45%（口服）<ref name = DP />
| protein_bound = 15–20%<ref name = DP />
| metabolism = 肝臟
| elimination_half-life = 2.5–3.5小時<ref name = DP />
| excretion = 腎臟（25–30%不變）<ref name = DP>Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.</ref>

<!--Identifiers-->
| IUPHAR_ligand = 7074
| CAS_number = 76824-35-6
| ATC_prefix = A02
| ATC_suffix = BA03
| PubChem = 3325
| DrugBank = DB00927
| ChemSpiderID = 3208
| UNII = 5QZO15J2Z8
| KEGG = D00318
| ChEBI = 4975
| ChEMBL = 902

<!--Chemical data-->
| C=8 | H=15 | N=7 | O=2 | S=3
| molecular_weight = 337.449 g/mol
| smiles = NS(=O)(=O)/N=C(\N)CCSCc1csc(n1)N=C(N)N
| StdInChI = 1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
| StdInChIKey = XUFQPHANEAPEMJ-UHFFFAOYSA-N
}}

'''法莫替丁'''（[[国际非专利药品名称|INN]]：famotidine），商品名稱為'''Pepcid'''，是一種[[组胺|组胺]][[H2受体阻抗剂|H<sub>2</sub>受体阻抗剂]]，主要用於抑制[[胃酸|胃酸]]的分泌，並用于治疗[[消化性溃疡|消化性溃疡]]和[[胃食道逆流|胃食道逆流]]。與[[西咪替丁|西咪替丁]]不同，法莫替丁等第二代[[H2受体阻抗剂|H<sub>2</sub>受體阻抗劑]]對[[細胞色素P450|細胞色素P450]]酶沒有明顯的抑制作用，因此法莫替丁的[[药物相互作用|药物相互作用]]並不明顯。<ref>{{Cite journal|title=Review article: drug interactions with agents used to treat acid-related diseases|author=Humphries TJ, Merritt GJ|url=http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.1999.00021.x/pdf|date=August 1999|journal=Aliment. Pharmacol. Ther.|issue=Suppl 3|doi=10.1046/j.1365-2036.1999.00021.x|volume=13|pages=18–26|format=pdf|pmid=10491725|access-date=2015-09-27|archive-url=https://web.archive.org/web/20151203044021/http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.1999.00021.x/pdf|archive-date=2015-12-03|dead-url=no}}</ref>法莫替丁於1979年首次發現，並在1981年投入市場。<ref name=Analogue2>{{Cite book|url=https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA4|title=Analogue-based Drug Discovery II|last=Fischer|first=Janos|date=2010|publisher=John Wiley & Sons|isbn=978-3-527-63212-1|page=4|access-date=2018-09-11|archive-date=2020-07-29|archive-url=https://web.archive.org/web/20200729125327/https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA4|dead-url=no}}</ref>

== 历史 ==
法莫替丁由{{tsl|en|Yamanouchi_Pharmaceutical|山之內製藥}}開發。<ref>[https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US4283408 US patent 4283408], Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 11 August 1981{{US patent reference|number=4283408 | y = 1981| m =08| d = 11|inventor=Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda|title=Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them}}</ref>[[默克藥廠|默克藥廠]]在20世紀80年代中期獲得法莫替丁的授權，<ref>{{Cite web|url=http://mediwire.skyscape.com/main/Default.aspx?P=Content&ArticleID=23882|title=Sankyo Pharma|accessdate=2009-10-31|year=2002|publisher=Skyscape Mediwire|archiveurl=https://web.archive.org/web/20090223125527/http://mediwire.skyscape.com/main/Default.aspx?P=Content&ArticleID=23882|archivedate=2009-02-23}}</ref>並由默克和[[強生公司|強生公司]]的合資企業銷售。在法莫替丁上，原本西咪替丁的[[咪唑|咪唑]]環被2-胍基[[噻唑|噻唑]]環取代。法莫替丁的效力比同為[[H2受體阻抗劑|H<sub>2</sub>受體阻抗劑]]的[[雷尼替丁|雷尼替丁]]高出9倍，更比[[西咪替丁|西咪替丁]]的效力高出32倍。<ref name=GE/>
法莫替丁在1986年由[[美國食品藥品監督管理局|美國食品藥品監督管理局]]批准在美國銷售。<ref>{{Cite web|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019462|accessdate=2018-09-11|title=Drugs@FDA: Pepcid|archive-date=2021-03-21|archive-url=https://web.archive.org/web/20210321092540/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019462|dead-url=no}}</ref>而商品名為Pepcid RPD的法莫替丁口腔崩散劑則於1998年獲得批准。<ref>{{Cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20752s000_PecidTOC.cfm|accessdate=2018-09-11|title=Drug Approval Package: Pecid RPD (Famotidine) NDA# 020752|archive-date=2021-03-31|archive-url=https://web.archive.org/web/20210331223035/https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20752s000_PecidTOC.cfm|dead-url=no}}</ref>法莫替丁的[[仿製藥|仿製藥]]在2001年開始上市，商品名包括Fluxid、Quamatel等。<ref>{{Cite web|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021712m|accessdate=2018-09-11|title=Drugs@FDA: Fluxid}}</ref>

在美國和加拿大，另有商品名為Pepcid Complete的複方咀嚼片，該藥品將法莫替丁與抗酸藥結合，以快速舒緩胃酸過多的症狀。<ref>{{Cite web|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020958|accessdate=2018-09-13|title=Drugs@FDA: Pepcid Complete|archive-date=2021-03-22|archive-url=https://web.archive.org/web/20210322065749/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020958|dead-url=no}}</ref>在英國，該藥品亦被稱為Pepcidtwo，但已在2015年4月停產。<ref>{{Cite web|url=http://www.medicines.org.uk/emc/medicine/20012|title=PepcidTwo Chewable Tablet|accessdate=2015-06-07|archive-url=https://web.archive.org/web/20160718071357/http://www.medicines.org.uk/emc/medicine/20012|archive-date=2016-07-18|dead-url=yes}}</ref>

因為法莫替丁在胃內的酸性環境下溶解度低，故此口服法莫替丁的[[生物利用度|生物利用度]]僅有50%。當法莫替丁與抗酸劑組合使用，抗酸劑能促進法莫替丁局部運送至[[胃壁細胞|胃壁細胞]]上的受體。因此，研究人員正在開發創新配方的口服片劑，例如胃滯留藥物輸送系統。胃滯留片劑能在胃內停留更久，從而改善生物利用度；而法莫替丁的局部運送還能增加胃壁受體部位的生物利用度，從而增強減少胃酸分泌的功效。<ref>{{Cite web|url=http://www.farmavita.net/content/view/1012/84/|title=Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine|accessdate=2009-01-31|year=2008|publisher=Farmavita.Net|archive-url=https://web.archive.org/web/20160329235131/http://www.farmavita.net/content/view/1012/84/|archive-date=2016-03-29|dead-url=yes}}</ref>

== 研究 ==
有些證據表示法莫替丁能作為治療抵抗[[精神分裂症|精神分裂症]]的附加治療。在一項試驗中，它使治療抵抗精神分裂症患者的症狀嚴重性降低了10%。<ref>{{Cite journal|title=A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.|last=Meskanen|first=K|last2=Ekelund, H|date=August 2013|journal=Journal of Clinical Psychopharmacology|issue=4|doi=10.1097/JCP.0b013e3182970490|volume=33|pages=472–478|pmid=23764683|last3=Laitinen, J|last4=Neuvonen, PJ|last5=Haukka, J|last6=Panula, P|last7=Ekelund, J}}</ref>

== 医疗用途 ==
{{Main article|H2受體阻抗劑}}
法莫替丁主要用於舒緩[[胃灼熱|胃灼熱]]和[[消化不良|消化不良]]<ref name="disease">[http://en.wikipedia.org/wiki/Australian_Medicines_Handbook Australian Medicines Handbook] {{Wayback|url=http://en.wikipedia.org/wiki/Australian_Medicines_Handbook |date=20201126092930 }}，2005. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-9-3。</ref>；治療[[胃及十二指肠潰瘍|胃及十二指肠潰瘍]]<ref name="disease"/>如{{tsl|en|Zollinger–Ellison_syndrome|佐埃二氏症}}和{{tsl|en|Multiple_endocrine_neoplasia|多發性內分泌腫瘤}}等病理性[[胃酸|胃酸]]過度分泌、<ref name=GE>{{cite journal|url=https://linkinghub.elsevier.com/retrieve/pii/S001650858580024X|issue=4|doi=10.1016/s0016-5085(85)80024-x|pages=1026–1033|title=Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome|volume=88|journal=Gastroenterology|date=1985-04|issn=0016-5085|accessdate=2018-09-11|author=J.M. Howard, A.N. Chremos, M.J. Collen, K.E. Mcarthur, J.A. Cherner, P.N. Maton, C.A. Ciarleglio, M.J. Cornelius, J.D. Gardner, R.T. Jensen|archive-date=2019-08-20|archive-url=https://web.archive.org/web/20190820135513/https://linkinghub.elsevier.com/retrieve/pii/S001650858580024X|dead-url=no}}</ref><ref name="mayo1">{{Cite web|url=https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/diagnosis-treatment/drc-20379046|title=Zollinger-Ellison syndrome - Diagnosis and treatment - Mayo Clinic|website=www.mayoclinic.org|language=en|access-date=2018-09-11|archive-date=2020-09-18|archive-url=https://web.archive.org/web/20200918142954/https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/diagnosis-treatment/drc-20379046|dead-url=no}}</ref>[[胃食道逆流|胃食道逆流]]（GERD）<ref name="disease"/>与{{tsl|en|Esophagitis|食道炎}}等上[[消化道|消化道]]病症。<ref name="mayo2">{{Cite web|url=https://www.mayoclinic.org/diseases-conditions/esophagitis/diagnosis-treatment/drc-20361264|title=Esophagitis - Diagnosis and treatment - Mayo Clinic|website=www.mayoclinic.org|language=en|access-date=2018-09-11|archive-date=2021-01-21|archive-url=https://web.archive.org/web/20210121174823/https://www.mayoclinic.org/diseases-conditions/esophagitis/diagnosis-treatment/drc-20361264|dead-url=no}}</ref>

雖然[[奧美拉唑|奧美拉唑]]可能更有效，法莫替丁也可作為治療[[幽門螺桿菌|幽門螺桿菌]]感染藥物的一部分。<ref>{{Cite journal|title=Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication|last=Kanayama|first=S|date=January 1999|journal=Nihon rinsho. Japanese journal of clinical medicine|issue=1|volume=57|pages=153–6|pmid=10036954}}</ref><ref>{{Cite journal|title=Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?|last=Soga|first=T|last2=Matsuura|first2=M|date=August 1999|journal=Journal of gastroenterology|issue=4|doi=10.1007/s005350050292|volume=34|pages=435–40|pmid=10452673|last3=Kodama|first3=Y|last4=Fujita|first4=T|last5=Sekimoto|first5=I|last6=Nishimura|first6=K|last7=Yoshida|first7=S|last8=Kutsumi|first8=H|last9=Fujimoto|first9=S}}</ref><ref>{{Cite journal|title=Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.|url=https://archive.org/details/sim_gut_1995-10_37_4/page/477|last=Borody|first=TJ|last2=Andrews|first2=P|date=October 1995|journal=Gut|issue=4|doi=10.1136/gut.37.4.477|volume=37|pages=477–81|pmc=1382896|pmid=7489931|last3=Fracchia|first3=G|last4=Brandl|first4=S|last5=Shortis|first5=NP|last6=Bae|first6=H}}</ref><ref>{{Cite journal|title=Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.|last=Hu|first=FL|last2=Jia|first2=JC|date=2003|journal=The Journal of international medical research|issue=6|doi=10.1177/147323000303100601|volume=31|pages=469–74|pmid=14708410|last3=Li|first3=YL|last4=Yang|first4=GB}}</ref><ref>{{Cite journal|title=[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].|last=Kirika|first=NV|last2=Bodrug|first2=NI|date=2004|journal=Terapevticheskii arkhiv|issue=2|volume=76|pages=18–22|pmid=15106408|last3=Butorov|first3=IV|last4=Butorov|first4=SI}}</ref><ref>{{Cite journal|title=Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.|last=Fujiwara|first=Y|last2=Higuchi|first2=K|date=June 2005|journal=Alimentary Pharmacology & Therapeutics|doi=10.1111/j.1365-2036.2005.02468.x|volume=21 Suppl 2|pages=10–8|pmid=15943841|last3=Nebiki|first3=H|last4=Chono|first4=S|last5=Uno|first5=H|last6=Kitada|first6=K|last7=Satoh|first7=H|last8=Nakagawa|first8=K|last9=Kobayashi|first9=K}}</ref>

法莫替丁也可用於预防因服用[[非甾体抗炎药|非甾体抗炎药]]所诱發的胃溃疡<ref>{{Cite journal|title=Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.|last=La Corte|first=R|last2=Caselli|first2=M|date=June 1999|journal=Drug safety|issue=6|doi=10.2165/00002018-199920060-00006|volume=20|pages=527–43|pmid=10392669|last3=Castellino|first3=G|last4=Bajocchi|first4=G|last5=Trotta|first5=F}}</ref><ref>{{Cite journal|title=Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.|last=Laine|first=L|last2=Kivitz|first2=AJ|date=March 2012|journal=The American Journal of Gastroenterology|issue=3|doi=10.1038/ajg.2011.443|volume=107|pages=379–86|pmc=3321505|pmid=22186979|last3=Bello|first3=AE|last4=Grahn|first4=AY|last5=Schiff|first5=MH|last6=Taha|first6=AS}}</ref>和減少手術後[[吸入性肺炎|吸入性肺炎]]的風險。<ref>{{Cite journal|title=Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.|url=https://archive.org/details/sim_british-journal-of-anaesthesia_1992-10_69_4/page/404|last=Escolano|first=F|last2=Castaño|first2=J|date=October 1992|journal=British journal of anaesthesia|issue=4|doi=10.1093/bja/69.4.404|volume=69|pages=404–6|pmid=1419452|last3=López|first3=R|last4=Bisbe|first4=E|last5=Alcón|first5=A}}</ref><ref>{{Cite journal|title=Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.|url=https://archive.org/details/sim_anaesthesia_1991-11_46_11/page/967|last=Vila|first=P|last2=Vallès|first2=J|date=November 1991|journal=Anaesthesia|issue=11|doi=10.1111/j.1365-2044.1991.tb09860.x|volume=46|pages=967–9|pmid=1750602|last3=Canet|first3=J|last4=Melero|first4=A|last5=Vidal|first5=F}}</ref><ref>{{Cite journal|title=Effects of famotidine on gastric pH and residual volume in pediatric surgery.|last=Jahr|first=JS|last2=Burckart|first2=G|date=July 1991|journal=Acta anaesthesiologica Scandinavica|issue=5|doi=10.1111/j.1399-6576.1991.tb03328.x|volume=35|pages=457–60|pmid=1887750|last3=Smith|first3=SS|last4=Shapiro|first4=J|last5=Cook|first5=DR}}</ref>

=== 劑型 ===
[[File:Gaster_Sales_In_China.jpg|thumb]]
[[File:Famotidine_20mg_generic.jpg|thumb]]20mg口服片]]
[[File:Famotidine_New_Package.jpg|thumb]]
某些法莫替丁的劑型可作為[[非處方藥|非處方藥]]銷售。如在[[美國|美國]]和[[加拿大|加拿大]]，10毫克和20毫克的法莫替丁口服片，有時與[[抗酸藥|抗酸藥]]組成[[複方|複方]]，可以作為非處方藥銷售。<ref>{{Cite web|url=https://www.nlm.nih.gov/medlineplus/druginfo/meds/a687011.html|title=Famotidine|access-date=2018-09-11|archive-url=https://web.archive.org/web/20160705112509/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a687011.html|archive-date=2016-07-05|dead-url=no}}</ref>較大劑量的法莫替丁仍然屬於[[處方藥|處方藥]]。法莫替丁與[[布洛芬|布洛芬]]的複方藥由{{tsl|en|Horizon_Pharma|Horizon Pharma}}以商品名稱Duexis銷售。<ref>Drugs.com [https://www.drugs.com/duexis.html duexis] {{Wayback|url=https://www.drugs.com/duexis.html |date=20170718023727 }}</ref>

== 副作用 ==
與法莫替丁相關的副作用包括[[頭痛|頭痛]]、[[頭暈|頭暈]]、[[便秘|便秘]]或[[腹瀉|腹瀉]]。<ref>{{Cite web|url=http://www.rxlist.com/cgi/generic/famot_ad.htm|title=Pepcid Side Effects & Drug Interactions|accessdate=2008-07-31|year=2008|publisher=RxList.com|archive-url=https://web.archive.org/web/20080906102308/http://www.rxlist.com/cgi/generic/famot_ad.htm|archive-date=2008-09-06|dead-url=yes}}</ref>

== 参考文献 ==
{{Reflist|3}}

== 參見 ==
* [[西咪替丁|西咪替丁]]
* [[雷尼替丁|雷尼替丁]]
* [[尼扎替丁|尼扎替丁]]

{{Histaminergics}}
{{消化道溃疡和胃食管反流病治疗药物}}

[[Category:脒|Category:脒]]
[[Category:胍|Category:胍]]
[[Category:H2受体拮抗剂|Category:H2受体拮抗剂]]
[[Category:噻唑|Category:噻唑]]
[[Category:硫醚|Category:硫醚]]